Metastatic Solid Tumor Clinical Trials in Detroit, Michigan
16 recruitingDetroit, Michigan
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting
Phase 1
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Endometrial CancerAdvanced Solid TumorMetastatic Solid Tumor+1 more
MOMA Therapeutics132 enrolled14 locationsNCT06974110
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid Tumor
Coherus Oncology, Inc.154 enrolled30 locationsNCT06657144
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.200 enrolled21 locationsNCT06521554
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1Phase 2
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Advanced or Metastatic Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.140 enrolled18 locationsNCT05023486
Recruiting
Phase 1
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited292 enrolled7 locationsNCT06724016
Recruiting
Phase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultRefractory Cancer
Sairopa B.V.130 enrolled7 locationsNCT05856981
Recruiting
Phase 1Phase 2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.840 enrolled74 locationsNCT05384626
Recruiting
Phase 1Phase 2
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Metastatic Solid TumorLocally Advanced Solid Tumor
Nuvalent Inc.359 enrolled63 locationsNCT05118789
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900